

Media Alert

**Issue Date: 25th April 2024**

For Immediate Release

**Berry Global Invests to Increase Production Capacity for Healthcare Products**

Berry Global Group, Inc., a leader in the design, development, and production of patient-centred [healthcare solutions](https://www.berryglobal.com/en/markets/healthcare), has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites.

Following the opening of its manufacturing facility and healthcare center of excellence in Bangalore, India, these latest investments underline Berry’s commitment to delivering high-quality [packaging](https://www.berryglobal.com/en/markets/healthcare/pharmaceutical-otc) and drug delivery devices that enhance the patient experience through improved medicine administration and adherence.

“As pharmaceutical innovations progress, so should the packaging and support that delivers each [dose](https://www.berryglobal.com/en/markets/healthcare/medical-devices). Berry Global is here to provide that expertise in the creation of patient-centred packages and [drug delivery](https://www.berryglobal.com/en/news/articles/berry-global-underlines-its-commitment-to-south-east-asia-region) device design,” said Walid Hamza, EVP Global Healthcare at Berry Global. “We continue to invest in the latest healthcare technologies to help our customers offer patients a safe and improved experience with every dose.”

Strategically located near pharmaceutical manufacturing and filling site hubs, Berry’s sites in Offranville, France, and Osnago, Italy help ensure fast response times and localised service. Investments at these sites will help ensure further supply chain reliability and consistent product availability while meeting the growing demand for Berry’s high value products and solutions in other regions of the world.

Berry’s Offranville site specialises in the manufacture of best-in-class standard and custom solutions for [pharmaceutical packaging](https://www.berryglobal.com/en/markets/healthcare/pharmaceutical-otc) and drug delivery devices, such as ophthalmic and nasal products, including the Rispharm multi-dose [eye dropper](https://www.berryglobal.com/en/news/articles/award-recognises-berry-healthcare-eye-dropper-innovation). Key investments at the site include new cleanroom production to ISO7 standard to help meet growing market demand, especially for Berry’s expertise as a contract development and manufacturing organisation (CDMO).

Investments at Berry’s Osnago site, which manufactures throat spray actuators, and Sirone site, which manufactures accompanying bottles, will support the growing demand for prescription and over-the-counter orally-administered solutions for the prevention and treatment of infections and [respiratory diseases](https://www.berryglobal.com/en/news/articles/berry-goes-beyond-drug-delivery-at-ddl-2023) driven by rising air pollution levels.

Learn more about how we are helping our healthcare customers deliver [enhanced patient experiences](https://www.berryglobal.com/en/markets/healthcare/drug-delivery)

**About Berry**

At Berry Global Group, Inc. (NYSE: BERY), we create innovative packaging solutions that we believe make life better for people and the planet. We do this every day by leveraging our unmatched global capabilities, sustainability leadership, and deep innovation expertise to serve customers of all sizes around the world. Harnessing the strength in our diversity and industry-leading talent of over 40,000 global employees across more than 250 locations, we partner with customers to develop, design, and manufacture innovative products with an eye toward the circular economy. The challenges we solve and the innovations we pioneer benefit our customers at every stage of their journey. For more information, visit our [website](https://www.berryglobal.com/en/), or connect with us on [LinkedIn](https://www.linkedin.com/company/berryglobal) or [X](https://twitter.com/BerryGlobalInc).

**Media Contact:**

Nielsen McAllister Public Relations Limited

+44 (0) 1322 293939

info@nmpr.co.uk

** ** 